Yuki Mukai1, Izumi Koike2, Tatsuya Matsunaga3, Naho Ruiz Yokota3, Hisashi Kaizu2, Shoko Takano2, Madoka Sugiura2, Eiko Ito2, Etsuko Miyagi3, Masaharu Hata2. 1. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan y_mukai@yokohama-cu.ac.jp. 2. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 3. Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abstract
BACKGROUND/AIM: The aim of this study was to define the outcome of radiation therapy for vulvar carcinoma, and to investigate the effectiveness of therapeutic and prophylactic inguinal lymph node (ILN) irradiation. Because reports about the treatment of ILN were limited. PATIENTS AND METHODS: Thirty consecutive vulvar carcinoma patients were treated using external beam radiation therapy (EBRT) for definitive disease (n=25) or postoperatively (n=5). Twenty-four (80%) had squamous cell carcinoma (SCC). Tumor stages (2002 UICC) ranged from 0 to IVB, with no distant metastases. RESULTS: The median total prescribed dose for primary tumor was 64.8 Gy. The 2-year overall survival rate was 25.3%. The outcome was significantly better in patients with ILNs<30 mm (p=0.005) and patients receiving prescribed doses >60 Gy (p=0.002). CONCLUSIONS: ILN diameters ≤30 mm and prescribed doses over 60 Gy were associated with ILN control in patients with vulvar carcinoma. Copyright
BACKGROUND/AIM: The aim of this study was to define the outcome of radiation therapy for vulvar carcinoma, and to investigate the effectiveness of therapeutic and prophylactic inguinal lymph node (ILN) irradiation. Because reports about the treatment of ILN were limited. PATIENTS AND METHODS: Thirty consecutive vulvar carcinomapatients were treated using external beam radiation therapy (EBRT) for definitive disease (n=25) or postoperatively (n=5). Twenty-four (80%) had squamous cell carcinoma (SCC). Tumor stages (2002 UICC) ranged from 0 to IVB, with no distant metastases. RESULTS: The median total prescribed dose for primary tumor was 64.8 Gy. The 2-year overall survival rate was 25.3%. The outcome was significantly better in patients with ILNs<30 mm (p=0.005) and patients receiving prescribed doses >60 Gy (p=0.002). CONCLUSIONS: ILN diameters ≤30 mm and prescribed doses over 60 Gy were associated with ILN control in patients with vulvar carcinoma. Copyright
Authors: David H Moore; Shamshad Ali; Wui-Jin Koh; Helen Michael; Mack N Barnes; Carolyn K McCourt; Howard D Homesley; Joan L Walker Journal: Gynecol Oncol Date: 2011-11-09 Impact factor: 5.482
Authors: Sushil Beriwal; Gaurav Shukla; Ashwin Shinde; Dwight E Heron; Joseph L Kelley; Robert P Edwards; Paniti Sukumvanich; Scott Richards; Alexander B Olawaiye; Thomas C Krivak Journal: Int J Radiat Oncol Biol Phys Date: 2012-12-27 Impact factor: 7.038
Authors: Nikhil G Thaker; Ann H Klopp; Anuja Jhingran; Michael Frumovitz; Revathy B Iyer; Patricia J Eifel Journal: Gynecol Oncol Date: 2014-12-16 Impact factor: 5.482
Authors: Mai Partridge Vandborg; René Depont Christensen; Jakob Kragstrup; Kasper Edwards; Peter Vedsted; Dorte Gilså Hansen; Ole Mogensen Journal: Int J Gynecol Cancer Date: 2011-08 Impact factor: 3.437
Authors: Raymond H Mak; Lia M Halasz; Cynthia K Tanaka; Marek Ancukiewicz; Delray J Schultz; Anthony H Russell; Akila N Viswanathan Journal: Gynecol Oncol Date: 2010-10-14 Impact factor: 5.482